Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Asthma, Chronic Rhinosinusitis With Nasa...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Asthma and chronic rhinosinusitis (CRS) are inflammatory diseases of the respiratory tract, asthma from the lower part, and CRS, from the upper part. In theory, these parts are correlated as if they are one single organ, namely "united airways", which means that if one is affected by any condition, the other might be impacted as well. However, this relationship has not yet been described down to the cellular and molecular levels. By investigating patients that have (1) asthma and CRS with nasal polyp, (2) asthma and CRS without nasal polyp, and (3) just CRS with nasal polyp, we aim to determine the correlation of the upper and lower part of the respiratory tract. At first, the characterization of disease will be determined by established clinical criteria, such as lung function, blood analysis for the presence of eosinophils (a type of white cells), and nasal polyp score. To continue, in-depth analysis of nose, oropharynx, and lung samples will help gain information about the inflammatory profile and local microbiome of the three different groups of patients through molecular and cellular assays. The results of this study will help to describe the hypothesis of the united airways which will provide better guidance for medical treatment of asthma and CRS with or without polyp, thus improving the life quality of patients.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Procedure: Blood sampling — Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
  • Procedure: Nasosorption — Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
  • Procedure: Oral sampling — For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
  • Procedure: Bronchoscopy — The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
  • Procedure: Nasal biopsy — Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
  • Procedure: Nasal sampling — Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
  • Procedure: Nasal mucosa mRNA sampling — Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
  • Diagnostic Test: Pregnancy test — In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.

Primary Outcomes

  • Inflammatory profile in different sections of the airways (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-09-01
Completion: 2026-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Principal Investigators:
  • Julia Eckl-Dorna, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of Vienna
  • Sven Schneider, MD (PRINCIPAL_INVESTIGATOR) - Medical University of Vienna
  • Marco Idzko, MD (PRINCIPAL_INVESTIGATOR) - Medical University of Vienna
Contact Information
Study Contact:
Julia Eckl-Dorna, PhD
+4314040034380
julia.eckl-dorna@meduniwien.ac.at
Sven Schneider, MD
+4314040034380
sven.schneider@meduniwien.ac.at
Marianne Rocha Hasler, PhD
014040034380
marianne.rochahasler@meduniwien.ac.at
Allgemeines Krankenhaus (AKH) Wien
Interventions
  • Procedure: Blood sampling — Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
  • Procedure: Nasosorption — Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
  • Procedure: Oral sampling — For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
  • Procedure: Bronchoscopy — The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
  • Procedure: Nasal biopsy — Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
Study Locations (1 sites)
Allgemeines Krankenhaus (AKH) Wien, Vienna, 1090 Austria
Eligibility Criteria
Inclusion Criteria: All patients who * 18-99 years of age * have a recorded clinical diagnosis of asthma (ICD-10 Code: J45) * undergo moderate-serve asthma treatment according to GINA/DAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy * Asthma treatment for a minimum of 12 weeks prior to screening visit * Group 1 and 2 - T2-high asthma with or without polyps: * FeNO \> 25 ppB * had either two times \>= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils \>= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils \> 2% within the last 12 months * Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines) * Group 3 - CRSwNP in absence of asthma: * Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines * Evidence of Type 2 inflammation: eosinophils \>= 250 cells/µl measured in the blood OR total IgE \>100 kU/L at the screening visit * Absence of asthma and N-ERD * Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed Exclusion Criteria: * Pregnancy (as determined by ß-HCG test) * Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity * Patients undergoing chronic oral corticosteroid therapy * Patients with any other confounding underlying lung disorder including but not limited to: * Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia * Cystic fibrosis, any known parasitic infections, and lung cancer * Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome * A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * Patients with clinically meaningful comorbidity as determined by the evaluating committee * Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit * Intake of a burst of systemic corticosteroids 4 weeks prior to any visit. * Immunosuppressive treatment (e.g. cyclosporine) * Drug and alcohol abuses * Current smoker * Former smoker if stopped smoking \<6 months and/or has \>10 pack-years
Conditions Asthma
Phase PHASE3
Enrollment 504
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: MG-K10/Placebo — MG-K10 Humanized Monoclonal Antibody Injection

Primary Outcomes

  • Primary purpose (52 weeks of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-25
Completion: 2028-01-15
Eligibility
Age: 12 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 504 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
Principal Investigators:
  • JingLi L Li, Medical Ph.D (STUDY_DIRECTOR) - The First Affiliated Hospital of Guangzhou University of Medical
Contact Information
Study Contact:
lipeng.liu L lipeng.liu, bachelor 02151371305 lipeng.liu@mabgeek.com, bachelor
02151371305
lipeng.liu@mabgeek.com
Jing Li, Medical Ph.D
The First Affiliated Hospital of Guangzhou Medical University
Interventions
  • Drug: MG-K10/Placebo — MG-K10 Humanized Monoclonal Antibody Injection
Study Locations (1 sites)
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion criteria: 1. Age between 12\~75 years old (including the critical value), male and female, weight ≥ 30kg; 2. Diagnosed with asthma for at least 1 year and current disease status that meets the diagnostic criteria of the 2024 GINA guidelines, and: 1\) Subjects have received moderate-high dose ICS therapy for at least 2 consecutive months before screening (see Appendix 5 for details, fluticasone propionate ≥250 μg twice a day, or an equivalent dose of ICS, no more than 2000 μg/day or equivalent dose of fluticasone propionate) combined with 1 control drug (such as LABA, LTRA, LAMA or extended-release theophylline), and maintained a stable treatment regimen and dose therapy for ≥ 1 month before baseline. Subjects using the third control drug can also participate in the study, but the subjects must also use the third control drug for at least 2 consecutive months before screening, and maintain a stable treatment regimen and dose treatment ≥ 1 month before baseline; 2) 1-second forced expiratory volume (FEV1) before bronchodilator use at the screening and baseline visits, measured ≤ 80% of the normal predicted value for adults and 90% of the normal predicted value ≤ for adolescents; 3) Asthma Control Questionnaire-5 (ACQ-5) score ≥ 1.5 points at the screening and baseline visits; 4) Must have experienced ≥ 1 acute exacerbation event within 12 months prior to screening: need to receive 1 ≥ systemic glucocorticoids (oral or intravenous) treatment due to asthma exacerbation or need hospitalization/emergency treatment; 5)A positive bronchodilator test (a ≥12% increase in FEV1 after inhalation of bronchodilators and an absolute increase in FEV1 ≥200 mL) will be acceptable for bronchodilator test results within 24 months prior to screening; Positive bronchodilator test (after inhaling a bronchodilator, the forced expiratory volume in one second (FEV1) increases by ≥12%, and the absolute value of FEV1 increases by ≥200 mL). The results of the bronchodilator test conducted within 24 months before screening are acceptable. 3.The subjects (including adolescents aged 12 years old ≤ age \< 18 years old) agree that they themselves and their partners will adopt effective contraceptive measures from the signing of the Informed Consent Form (ICF) until 6 months after the last administration of the drug. 4.The subject and his/her guardian (applicable to adolescents aged 12 years old ≤ age \< 18 years old) are able to understand the procedures and methods of this study, willing to sign the Informed Consent Form, strictly abide by the clinical research protocol to complete the study, and capable of independently completing the study-related questionnaires. Exclusion criteria: 1. Subjects with known hypersensitivity to the investigational product or its excipients; 2. Subjects who, within 1 month prior to screening and drug administration, have required systemic glucocorticoid therapy (oral or intravenous) for asthma exacerbation at least once, or have required hospitalization/emergency treatment due to asthma exacerbation. 3. Subjects who, within 1 month prior to screening and drug administration, have required at least one course of systemic glucocorticoid therapy (oral or intravenous administration) for asthma exacerbation, or have required hospitalization or emergency treatment due to asthma exacerbation. 4. Subjects who have received systemic glucocorticoid therapy from 1 month before screening until drug administration (excluding those with topical, ophthalmic, or intranasal glucocorticoid use) 5. Subjects who have received intravenous immunoglobulin (IVIG) therapy or allergen-specific immunotherapy (SIT) within 1 month prior to drug administration. 6. Subjects who have undergone major surgery within 8 weeks prior to screening have scheduled major surgery during the study period, including inpatient and day-case outpatient procedures. 7. Subjects with a history of substance abuse or illicit drug use. 8. Subjects with any other conditions that, in the investigator's judgment, may compromise subject safety or trial integrity.

Home Hospital for Suddenly Ill Adults

NCT03524222
Recruiting
Conditions Infection, Heart Failure, COPD, Asthma, ...
Phase NA
Enrollment 3000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Home Hospitalization — See above

Primary Outcomes

  • Total direct cost of hospitalization, $ (From date of admission to date of discharge, an expected average of 4 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-01-18
Completion: 2031-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Contact Information
Study Contact:
David M Levine, MD MPH MA
617-732-7063
dmlevine@partners.org
Jeffrey L Schnipper, MD MPH
617-732-7063
jschnipper@partners.org
David M Levine, MD MPH MA
617-732-7063
dmlevine@partners.org
Brigham and Women's Hospital
Interventions
  • Other: Home Hospitalization — See above
Study Locations (2 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Brigham and Women's Faulkner Hospital, Boston, Massachusetts 02130 United States
Eligibility Criteria
Inclusion Criteria: * Resides within either a 5-mile or 20 minute driving radius of emergency department * Has capacity to consent to study OR can assent to study and has proxy who can consent * \>= 18 years-old * Can identify a potential caregiver who agrees to stay with patient for first 24 hours of admission. Caregiver must be competent to call care team if a problem is evident to her/him. After 24 hours, this caregiver should be available for as-needed spot checks on the patient. This criterion may be waived for highly competent patients at the patient and clinician's discretion. * Primary or possible diagnosis of cellulitis, heart failure, complicated urinary tract infection, pneumonia, COPD/asthma, other infection, chronic kidney disease, malignant pain, diabetes and its complications, gout flare, hypertensive urgency, previously diagnosed atrial fibrillation with rapid ventricular response, anticoagulation needs, or a patient who desires only medical management that requires inpatient admission, as determined by the emergency room team. Exclusion Criteria: * Undomiciled * No working heat (October-April), no working air conditioning if forecast \> 80°F (June-September), or no running water * On methadone requiring daily pickup of medication * In police custody * Resides in facility that provides on-site medical care (e.g., skilled nursing facility) * Domestic violence screen positive * Acute delirium, as determined by the Confusion Assessment Method * Cannot establish peripheral access in emergency department (or access requires ultrasound guidance) * Secondary condition: end-stage renal disease, acute myocardial infarction, acute cerebral vascular accident, acute hemorrhage * Primary diagnosis requires multiple or routine administrations of intravenous narcotics for pain control * Cannot independently ambulate to bedside commode * As deemed by on-call medical doctor, patient likely to require any of the following procedures: computed tomography, magnetic resonance imaging, endoscopic procedure, blood transfusion, cardiac stress test, or surgery * High risk for clinical deterioration * Home hospital census is full (maximum 5 patients at any time)
Conditions Asthma
Phase PHASE3
Enrollment 370
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.
  • Drug: Standard of care — Standard of care will be administered.

Primary Outcomes

  • Annualized rate of clinically significant asthma exacerbations (Up to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-27
Completion: 2029-12-28
Eligibility
Age: 12 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 370 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.
  • Drug: Standard of care — Standard of care will be administered.
Study Locations (1 sites)
GSK Investigational Site, Miami Lakes, Florida 33014-2479 United States
Eligibility Criteria
Inclusion Criteria: * Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in Informed consent form (ICF), For participants aged 12 to 17 years, signed assent must be obtained from the participant in addition to signed consent from their Legally acceptable representative (LAR). * Participants aged 12 to 80 years at the time of signing the informed consent. * Male or eligible female participants: * Female participants: * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i. Is a Participant of non-childbearing potential (PONCBP) or ii. Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<) 1 percent (%), 28 days prior to the first dose of the study drug, and during the study intervention period and follow-up period for at least 60 weeks after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention. * A POCBP must have a negative serum pregnancy test at screening and a highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before each dose of study intervention. * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Contraceptive use by women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical trials. * A documented physician diagnosis of asthma for at least 12 months prior to Visit 1, according to the Global Initiative for Asthma (GINA) 2026 guidelines. * Evidence of variable airflow obstruction consistent with asthma. * Documented history of asthma exacerbation within 12 months prior to Visit 1. * A well-documented requirement for regular treatment with medium or high dose Inhaled corticosteroid (ICS) for at least 3 months prior to screening with or without maintenance oral corticosteroids (OCS). * At least 1 additional maintenance asthma controller medication is required according to standard practice of care (e.g., Long-acting beta-2 agonist \[LABA\], Leukotriene receptor antagonists \[LTRA\], theophylline, Long-acting muscarinic agonists \[LAMA\], chromones, etc.). Use of additional asthma controller medications must be documented for at least 3 months prior to screening. * Uncontrolled asthma based on ACQ-5 score. Exclusion Criteria: * Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of participant safety or study results. * History of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix). * Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia. * New York Heart Association (NYHA) class III or IV heart failure. * Other significant medical conditions that could impact participants' safety or study outcomes. * History of an unresolved clinically significant infection within 30 days prior to Visit 1. * A known immunodeficiency other than that explained by the use of corticosteroids taken as therapy for asthma. * Receipt of any marketed or investigational biologic agent or investigational non-biologic agent, prior to Visit 1. * Use of systemic immunosuppressive medication within 3 months prior to Visit 1 (other than systemic corticosteroid burst or stable maintenance OCS for treatment of asthma). * Current smokers (tobacco and/or marijuana), current users of vaping products/electronic-cigarettes or participants with a smoking history \>=10 pack-years.
Conditions Depressive Disorder, Post-Acute COVID-19...
Phase NA
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a monocentric, randomized pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological and clinical outcomes in patients with depression and comorbid Post-COVID-19 condition (PCC). Participants will be randomized into two arms, both receiving a total of 30 active iTBS sessions applied to the left dorsolateral prefrontal cortex (DLPFC) at 90% resting motor threshold using a PowerMAG 100 ppTMS stimulator: * Standard Arm: One iTBS session per day, five days per week, over six weeks. * Intensified Arm: Six iTBS sessions per day, approximately one-hour apart, over five consecutive days. The primary outcomes are changes in immunological blood markers (C-reactive protein \[CRP\], tumor necrosis factor \[TNF\], interleukin-1β \[IL-1β\], interleukin-6 \[IL-6\]) and depressive symptomatology measured by Beck Depression Inventory-II (BDI-II) and Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes include fatigue (Fatigue Severity Scale \[FSS\], Fatigue Scale for Motor and Cognitive Functions \[FSMC\], Post-Exertional Malaise questionnaire \[PEM\]), sleep quality (Pittsburgh Sleep Quality Index \[PSQI\]), daytime sleepiness (Epworth Sleepiness Scale \[ESS\]), functioning (Sheehan Disability Scale \[SDS\]), anxiety (Beck Anxiety Inventory \[BAI\]) and an exploratory adverse effect screening. Follow-up assessments will be performed three days after treatment completion and again at three months post-intervention to evaluate both short- and medium-term effects. Biospecimen collection will include approximately 141 ml of peripheral blood per participant across three time points (baseline, post-treatment, +3 days). Samples will be analyzed for inflammatory markers and securely stored in the institutional biobank of the Max Planck Institute of Psychiatry in accordance with data protection and ethical guidelines. Safety and tolerability will be continuously monitored, including documentation of adverse events. The results of this pilot study are expected to provide preliminary evidence on whether accelerated iTBS protocols may exert differential effects on neuroinflammatory processes and depressive symptomatology in patients with Post-COVID-19 condition, thereby informing larger controlled clinical trials.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS — iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.

Primary Outcomes

  • Change in immunophenotypic marker CRP from baseline to post-treatment (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment)
  • Change in immunophenotypic marker TNF from baseline to post-treatment (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment)
  • Change in immunophenotypic marker IL-1ß from baseline to post-treatment (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment)
  • Change in immunophenotypic marker IL-6 from baseline to post-treatment (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment)
  • Total score change in the Becks Depression Inventory, version 2 (BDI-II, self-rating) (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment, follow-up 3 months after treatment completion)
  • Total score change in the clinician-rated Montgomery Asberg Depression scale (MADRS) (baseline (day of first treatment), day of 15th treatment, 3 days after 30th (last) treatment, follow-up 3 months after treatment completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-11
Completion: 2027-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Max-Planck-Institute of Psychiatry
Principal Investigators:
  • Angelika Erhardt-Lehmann, MD, Prof. (PRINCIPAL_INVESTIGATOR) - Max-Planck-Institute of Psychiatry
Contact Information
Study Contact:
Alexandros Balaskas, MD
0049-089-30622-1402
Ambulanz@psych.mpg.de
Angelika Erhardt-Lehmann, MD, Prof.
Reception Outpatient Clinic
0049-089-30622-1402
Ambulanz@psych.mpg.de
Max-Planck-Institute of Psychiatry
Interventions
  • Device: Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS — iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.
Study Locations (1 sites)
Max-Planck-Institute of Psychiatry, Munich, Bavaria 80804 Germany
Eligibility Criteria
Inclusion Criteria: * Age 18-65 years * Capacity to consent (legally competent, written informed consent including data protection) * Diagnosis of depression (at least moderate severity, BDI-II ≥ 20), including major depressive episode in bipolar disorder * Comorbid diagnosis of Post-COVID-19 condition (WHO definition) * Insufficient improvement of depressive symptoms under psychopharmacological treatment * Stable psychopharmacological medication for at least 4 weeks prior to start of iTBS Exclusion Criteria: * Age \<18 years or \>65 years * Pregnancy, planned pregnancy, or breastfeeding * Legal guardianship or cognitive impairment preventing valid informed consent * Severe developmental disorder or intellectual disability * Acute or chronic substance abuse (alcohol, prescription drugs, or illicit drugs) * Current treatment with benzodiazepines or Z-substances * Acute suicidality * Psychotic symptoms * Severe neurological disorder (e.g., major brain injury, neurodegenerative disease) * Ongoing treatment with another neurostimulation method (ECT, TMS, VNS) * Contraindications to TMS, including: Intracranial metal, implants, shunts, Cochlear implant, pacemaker, implantable defibrillator, History of seizures or epileptiform EEG * Severe general medical illness (e.g., anemia requiring transfusion, severe arrhythmias, cardiomyopathy)
Conditions Depressive Symptoms, Quality of Life, Co...
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Despite its significant impact on individuals and healthcare systems, substantial gaps remain in the clinical and rehabilitative management of depression in oncology patients. Depression in cancer patients is often under-recognized and untreated, and screening tools and structured healthcare pathways are lacking. Even when depression is identified in oncology patients, evidence of effective treatments is limited. There are no specific guidelines for psychotropic drug use in cancer patients, and antidepressant efficacy is uncertain despite their frequent use. Emerging strategies like transcranial magnetic stimulation and cognitive rehabilitation show promising findings. However, the cost-effectiveness of therapeutic strategies is understudied. Repetitive transcranial magnetic stimulation (rTMS) is already used for the treatment and relapse prevention of depression both as monotherapy and as an add-on to antidepressant pharmacotherapy, and it appears effective in improving cognitive performance. However, it has not yet been applied to treat depressive disorders in oncology patients. Virtual reality-based cognitive behavioral intervention (VR-COG) is designed to improve cognitive functioning, a central feature of depression in oncological conditions. VR-COG enhances learning and skill acquisition with better ecological efficiency than traditional cognitive remediation programs. VR approaches are well-received by oncology patients and show promise in reducing anxiety and depressive symptoms. The trial aims to evaluate the effectiveness of highly specialized, nonpharmacological interventions on depressive symptoms and quality of life in oncology patients. Specifically, repetitive Transcranial Magnetic Stimulation (rTMS) and Virtual Reality-based Cognitive Remediation (VR-COG) will be analyzed, alongside standard Treatment as Usual (TAU), in comparison to TAU alone. This trial also aims at evaluate cognitive functioning, depression-related conditions and the cost-effectiveness of the interventions under study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Device: Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU) — The "CEREBRUM-VELA" virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
  • Device: Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU) — Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
  • Other: Treatment as Usual (TAU) — Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).

Primary Outcomes

  • Hamilton Depression rating scale (HAM-D 17) (T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1))
  • Dropout rates; Proportion of recruited participants among those considered eligible (T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1))
  • Simulator Sickness Questionnaire (SSQ) (T0 (0 months - baseline); T1 (3 months - post intervention))
  • TMSens_Q (T0 (0 months - baseline); T1 (3 months - post intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-21
Completion: 2027-12-31
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital of Ferrara
Collaborators: University Hospital of Cagliari
Principal Investigators:
  • Luigi Grassi, MD, PhD (PRINCIPAL_INVESTIGATOR) - Università degli Studi di Ferrara
Contact Information
Study Contact:
Martino Belvederi Murri, MD
00393335248720
martino.belvederimurri@unife.it
Barbara Zaccagnino, PsyD
00393288657355
barbara.zaccagnino@edu.unife.it
Martino Belvederi Murri, MD
0039 3335248720
martino.belvederimurri@unife.it
Health Trust, Ferrara
Interventions
  • Device: Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU) — The "CEREBRUM-VELA" virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
  • Device: Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU) — Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
  • Other: Treatment as Usual (TAU) — Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
Study Locations (2 sites)
Health Trust, Ferrara, Ferrara, FE 44124 Italy
University Hospital of Cagliari, Cagliari, 09124 Italy
Eligibility Criteria
Inclusion Criteria: * Diagnosis of oncological disease in the last 5 years * Diagnosis of Major Depressive Disorder, without psychotic symptoms, according to DSM-5 criteria * 17-item Hamilton Rating Scale for Depression (HAM-D-17) (score ≥14) * Age: 18 years or older * Oncological disease in a non-advanced stage (Karnofsky Performance Status \> 80) Exclusion Criteria: * Current or prior hospitalization in the next 6 months * Planned surgery in the next 6 months * Suicidal ideation * Substance use * History of significant head trauma, neurological disorders, intellectual deficits * Recurrent seizures resulting from head trauma or conditions lowering seizure threshold * Concurrent use of medications that increase the risk of epileptic seizures (e.g., antipsychotics, tricyclics, theophylline) * Glaucoma, retinal detachment, or other serious vision impairments that may prevent the use of virtual reality technology * Severe problems with autonomous ambulation
Conditions Unipolar Depression
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

It is evident from recent studies that cognitive deficits persist even after remission of depressive episode. Hence, in this study, the investigators would like to see whether specific Yoga practice will help in enhancing cognitive abilities in this population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Adjuvant yoga intervention — The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.

Primary Outcomes

  • Working memory (Digit Span) (Baseline, after six weeks yoga and after four weeks of completion of yoga)
  • Attention and processing speed(Trail A and B) (Baseline, after six weeks yoga and after four weeks of completion of yoga)
  • Cognitive flexibility (Baseline,after six weeks yoga and after four weeks of completion of yoga)
  • Cognitive inhibition (Baseline,after six weeks yoga and after four weeks of completion of yoga)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-17
Completion: 2027-06-30
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: Fogarty International Center of the National Institute of Health, National Institute of Mental Health and Neuro Sciences, India
Principal Investigators:
  • Vishwajit L Nimgaonkar, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Vishwajit L Nimgaonkar
4127265164
vishwajitnl@upmc.edu
Triptish Bhatia
+919910107210
trb16@pitt.edu
Daiveek G Pattanashetty, MD
+919482023658
daiveek1991@gmail.com
National Institute of Mental Health and Neuroscience (NIMHANS)
Interventions
  • Behavioral: Adjuvant yoga intervention — The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
Study Locations (1 sites)
National Institute of Mental Health and Neuroscience (NIMHANS), Bengaluru, Karnataka 560029 India
Eligibility Criteria
Inclusion Criteria: * Age more than 18years and less than 60 years * H/o at least one depressive episode which is under remission and at the time of examination and throughout the study duration, * Informed Consent Exclusion Criteria: * Comorbid Psychosis, OCD, Bipolar disorder * Comorbid ADHD, IDD * Comorbid substance dependence (except tobacco) * Comorbid major or minor cognitive impairment, * Bi temporal ECT within 6 months * Past yoga practice - regularly for 1 month within 3 months Pregnancy
Conditions Depression
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this exploratory, mixed-method design study is to gather qualitative and quantitative data obtained through interviews and questionnaires with veterans who are currently enrolled at the VA for healthcare. The main question this study aims to answer is: How do veterans aged 65+ who are enrolled for care at the VA understand ketamine assisted psychotherapy for depression and for end-of-life distress? Using a story-completion approach, participants will be provided with a brief story starter involving a fictitious character and scenario and asking them to complete the story. Few contextual details will be offered about the character. In responding to ambiguous cues, participants are thought to project their conscious and subconscious perceptions about the phenomenon in question onto the story, a useful method for exploring stigmatized topics. The purpose of this exercise is to ascertain the participants attitudes and perceptions regarding ketamine assisted psychotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Patient Health Questionnaire 9 (2 weeks)
  • Ten Item Personality Inventory (2 weeks)
  • Death Anxiety Questionnaire (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-08
Completion: 2025-04
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Albany Research Institute, Inc.
Principal Investigators:
  • Caitlin Holley, Ph.D. (PRINCIPAL_INVESTIGATOR) - Albany Research Institute, Inc.
Contact Information
Study Contact:
Caitlin Holley, Ph.D.
518-626-5365
caitlin.holley@va.gov
Stacey Farmer, Ph.D.
518-798-6066
stacey.farmer@va.gov
Caitlin Holley, Ph.D.
518-626-5365
caitlin.holley@va.gov
Stratton VA Medical Center
Interventions
N/A
Study Locations (1 sites)
Stratton VA Medical Center, Albany, New York 12208 United States
Eligibility Criteria
Inclusion Criteria: * Veterans enrolled in VA care. * Age 65 or older. * Fluent in written and spoken English. Exclusion Criteria: * Cognitively impaired to the extent that patient cannot comprehend the survey.
Conditions Emotional Distress, Cardiac Arrest (CA),...
Phase NA
Enrollment 84
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to pilot two resilience interventions for cardiac arrest survivors and their informal caregivers, Recovering Together after Cardiac Arrest 1 and Recovering Together after Cardiac Arrest 2 . The data the investigators gather in this study will be used to further refine the interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Recovering Together after Cardiac Arrest 1 — The intervention will teach resiliency skills (mindfulness and coping) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person until the survivor is discharged; remaining sessions will occur over Zoom.
  • Other: Recovering Together after Cardiac Arrest 2 — In this minimally enhanced usual care control, dyads will participate in one 30-minute session with a clinician at beside to review a pamphlet of available psychosocial resources for cardiac arrest survivors and their caregivers.

Primary Outcomes

  • Feasibility of Recruitment (pre-test)
  • Feasibility of Randomization (The end of treatment at 6 weeks)
  • Feasibility of Assessment Completion (pre-test, the end of treatment at 6 weeks, and 3 months after the end of treatment)
  • Feasibility of Program Adherence (RT-CA 1) (the end of treatment at 6 weeks)
  • Therapist Fidelity (the end of treatment at 6 weeks)
  • Treatment Satisfaction (RT-CA 1) (the end of treatment at 6 weeks)
  • Credibility (RT-CA 1) (pre-test)
  • Expectancy (RT-CA 1) (pre-test)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-17
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: National Center for Complementary and Integrative Health (NCCIH)
Principal Investigators:
  • Alexander Presciutti, PhD (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Alexander Presciutti, PhD
332-877-28146
alexander.presciutti@mountsinai.org
Georgia Cosola, MA
332-877-2814
georgia.cosola@mountsinai.org
Interventions
  • Behavioral: Recovering Together after Cardiac Arrest 1 — The intervention will teach resiliency skills (mindfulness and coping) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person until the survivor is discharged; remaining sessions will occur over Zoom.
  • Other: Recovering Together after Cardiac Arrest 2 — In this minimally enhanced usual care control, dyads will participate in one 30-minute session with a clinician at beside to review a pamphlet of available psychosocial resources for cardiac arrest survivors and their caregivers.
Study Locations (2 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Mount Sinai Health System, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Out-of-hospital or in-hospital CA survivor (must have new diagnosis of "cardiac arrest" in electronic medical record from index hospitalization with documented loss of pulse) with an identified caregiver (identified by the survivor who is their primary source of emotional and functional support) * survivor must score \>5 on Short Form of the Mini Mental State Exam for sufficient cognitive function for meaningful participation * ability and willingness to participate in a hybrid in-person/live video intervention * English speaking adults (18 year or older) * at least one member of the dyad endorses clinically significant emotional distress during screening (\>7 on either of the Hospital Anxiety and Depression Scale subscales). Exclusion Criteria: * active psychosis, mania, substance dependence, or suicidal intent or plan that would require a higher level of care * any other psychiatric or neurological condition that would preclude meaningful participation * the caregiver must not be a cardiac arrest survivor
Conditions Cardiac Arrest, Anxiety Depression, Fami...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This pilot randomized controlled trial (RCT) will test the feasibility and acceptability of the informational intervention program, Heartsight, to reduce caregivers' uncertainty experienced throughout their child's illness trajectory after cardiac arrest. The investigator aims to enroll up to 30 caregivers of pediatric cardiac arrest patients to (Aim 1a) pilot recruitment and randomization (2:1) procedures, and (Aim 1b) estimate retention rate at 3 months and assess engagement and utilization metrics for frequency of access and time spent on each module of the informational packages. The investigator also aims to evaluate the association of the intervention with efficacy outcomes in an exploratory manner in preparation for a larger trial, including (Aim2a) a preliminary estimate of the association of intervention with the surrogate's uncertainty levels at 3 months post-discharge, and (Aim 2b) a preliminary estimate of the association of intervention with the surrogate's anxiety, depression, and post-traumatic stress symptoms at 3 months post-discharge.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Education Intervention — Caregivers will receive education modules at multiple time points during their children's post cardiac arrest recovery trajectory

Primary Outcomes

  • Retention Rate (3 months post enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-05-31
Eligibility
Age: 0 Days – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Philadelphia
Contact Information
Study Contact:
Elizabeth Herrup, MD
215-514-0166
herrupe@chop.edu
Elizabeth Herrup, MD
215-514-0166
herrupe@chop.edu
Children's Hospital of Philadelphia
Interventions
  • Other: Education Intervention — Caregivers will receive education modules at multiple time points during their children's post cardiac arrest recovery trajectory
Study Locations (1 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: Caregiver 1. Caregiver of a child \<17.5 years of age who had at least a 2 minute cardiac arrest, is expected to be discharged within 30 days, and to survive at least 3 months post-discharge from hospital. 2. English speaking Child 1. \<17.5 years of age 2. Have had a cardiac arrest lasting more than 2 minutes within the past 7 days and have not yet been discharged from pediatric intensive care unit (PICU) or cardiac intensive care unit (CICU) Exclusion Criteria: 1\) Parent or legal guardian is not the child's caregiver
Conditions Opioid Use, Stimulant Use, Depression an...
Phase PHASE2
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment. Participants are recruited from community-based substance use treatment facilities and recovery services. Participants must be adults who have or are currently using opioids and/or stimulants.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: uMAT-R + enhanced community engagement — uMAT-R + enhanced community engagement involves an optimized community engagement strategy employed by the intervention team. This involves in-person interactions with eligible participants and recruitment sites.
  • Behavioral: Original uMAT-R supplementary mHealth recovery intervention — uMAT-R supplementary mHealth recovery intervention is the original intervention without optimization of the community engagement approach.

Primary Outcomes

  • Abstinence/ Changes in Substance Use (Time 0 (Baseline) and Time 1 (One Month))
  • Opioid use/ Stimulant use disorder symptoms (Time 0 (Baseline) and Time 1 (One Month))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-31
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Contact Information
Study Contact:
Hannah Szlyk
917-836-4225
szlyk@wustl.edu
Elecia Worley
e.m.worley@wustl.edu
Hannah Szlyk, PhD
917-836-4225
szlyk@wustl.edu
Washington University School of Medicine
Interventions
  • Behavioral: uMAT-R + enhanced community engagement — uMAT-R + enhanced community engagement involves an optimized community engagement strategy employed by the intervention team. This involves in-person interactions with eligible participants and recruitment sites.
  • Behavioral: Original uMAT-R supplementary mHealth recovery intervention — uMAT-R supplementary mHealth recovery intervention is the original intervention without optimization of the community engagement approach.
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Have a history of opioid and/or stimulant use * Identify as Black and/or African American * Seek treatment at local substance use treatment centers * Fluent in English * U.S. resident * 18 years of age or older at the time of data collection. Exclusion Criteria: * Self-reported cognitive impairment that would limit ability to participate in research.
Conditions Postpartum Depression (PPD)
Phase NA
Enrollment 130
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Although the transition to motherhood is often a joyful experience, there is evidence that teenage motherhood can present many stressful challenges, potentially leading to the development of postpartum depression. Postpartum depression (PPD) remains a public health issue with negative consequences for both mothers and their babies. The aim of this study is to assess the feasibility of implementing childbirth education underpinned by salutogenic and self-efficacy perspectives among teenage mothers in low-income settings. The study also aims to provide preliminary findings on the intervention's effectiveness in preventing postpartum depression among Ethiopian teenage mothers. The theoretical based childbirth education approach can enhance the psychosocial well-being of first-time teenage mothers. The intervention consists of six sessions: three during the antenatal period and three in the postpartum period. These sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion (each lasting 90-120 minutes), as supported by the existing evidence. The study expected to support the feasibility of the study design. Preliminary findings are anticipated to show a significant difference in postpartum depression scores between the intervention and control groups, with teenage mothers in the intervention group having a lower risk of postpartum depression compared to those in the control group. Integrating sense of coherence and self-efficacy theories into maternity care services could provide empirical support for preventive efforts against postpartum depression. The findings of this study may address research gaps regarding the psychosocial wellbeing of teenage mothers, serving as baseline evidence for large scale interventional studies that consider the sociocultural and economic contexts of low-income countries.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Childbirth education programme — The intervention framework is underpinned by a converging of salutogenic and self-efficacy perspectives, aiming to enhance mothers' ability to adapt to new motherhood life despite stressors, and to address the question, "How do teenage mothers stay well despite stressful events of transition to motherhood?" The intervention consists of six sessions: three of which will be provided in the antenatal period and the other three in the postpartum period. The sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion sessions (each lasting 90-120 minutes), as supported by the existing evidence.
  • Other: Usual Care — The control group will receive the usual maternity care.

Primary Outcomes

  • Edinburgh Postnatal Depression Scale (6 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-05
Completion: 2025-07-15
Eligibility
Age: 13 Years – 19 Years
Sex: FEMALE
Volunteers: true
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Contact Information
Study Contact:
Lebeza Alemu Tenaw
52242797
lebeza.tenaw@connect.polyu.hk
Temesgen Mekonnen
0913512832
temesgenm@gmail.com
Felege Hiwot Specialized Hospital
Interventions
  • Behavioral: Childbirth education programme — The intervention framework is underpinned by a converging of salutogenic and self-efficacy perspectives, aiming to enhance mothers' ability to adapt to new motherhood life despite stressors, and to address the question, "How do teenage mothers stay well despite stressful events of transition to motherhood?" The intervention consists of six sessions: three of which will be provided in the antenatal period and the other three in the postpartum period. The sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion sessions (each lasting 90-120 minutes), as supported by the existing evidence.
  • Other: Usual Care — The control group will receive the usual maternity care.
Study Locations (4 sites)
Addis Alem Hospital, Bahir Dar, Amhara Ethiopia
Felege Hiwot Specialized Hospital, Bahir Dar, Amhara Ethiopia
Tibebe Gion Hospital, Bahir Dar, Amhara Ethiopia
Dessie Specialized Hospital, Dessie, Amhara Ethiopia
Eligibility Criteria
Inclusion Criteria: * married first-time teenage mothers aged 13-19 years attending antenatal follow-up in the selected hospitals * a single pregnancy with 28-30 weeks of gestational age * no pregnancy complications contraindicating vaginal delivery * plan to have institutional delivery and postnatal visits at the selected health hospitals and who reside for a minimum of 12 weeks postdelivery around the selected hospitals Exclusion Criteria: * have self-reported history or current mental health problems * participated in similar interventional programmes * have serious medical and obstetrics problems * having foetus with diagnosed congenital anomalies